Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Mogrify Limited and the MRC Laboratory of Molecular Biology (LMB), today announced an exploratory research collaboration.

11 Jan 2021

Researchers receive NIH grant to develop more effective flu vaccines

To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.

11 Jan 2021

Study shows P681H mutation is becoming globally prevalent among SARS-CoV-2 sequences

In a recent bioRxiv preprint study, researchers from the University of Hawaii showed that the S gene of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating according to the sequence and phylogenetic analysis.

10 Jan 2021

Single-dose nanoparticle vaccine for SARS-CoV-2

Before the pandemic, the lab of Stanford University biochemist Peter S. Kim focused on developing vaccines for HIV, Ebola and pandemic influenza.

8 Jan 2021

New approach to tame botulinum toxin for drug delivery

While rare, botulism can cause paralysis and is potentially fatal. It is caused by nerve-damaging toxins produced by Clostridium botulinum -- the most potent toxins known.

8 Jan 2021

Single-dose nanoparticle COVID-19 vaccine elicits virus-neutralizing antibody response in mice

Across the world, health care workers and high-risk groups are beginning to receive COVID-19 vaccines, offering hope for a return to normalcy amidst the pandemic.

8 Jan 2021

Study reveals six-month consequences of COVID-19 in patients discharged from hospital

More than three quarters of COVID-19 patients have at least one ongoing symptom six months after initially becoming unwell, according to research published in The Lancet.

8 Jan 2021

Scientists gain new insight into how the immune system can be better used to destroy cancer cells

Scientists at the University of Southampton's Centre for Cancer Immunology have gained new insight into how the immune system can be better used to find and kill cancer cells.

8 Jan 2021

UCSF researchers discover a new way to control immune system's 'natural killer' cells

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection.

8 Jan 2021

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

Researchers at Carnegie Mellon University report findings on an advanced nanomaterial-based biosensing platform that detects, within seconds, antibodies specific to SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

8 Jan 2021

How do SARS-CoV-2 antibodies change over time in recovered patients?

Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.

8 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Gut and oral microbiomes predict COVID-19 severity

One question that continues to remain unanswered during the ongoing coronavirus disease 2019 (COVID-19) pandemic has been why is there a distinctive hit-and-miss pattern when it comes to severe disease? An interesting new study that appears on the medRxiv* preprint server pinpoints one highly relevant risk factor: the state of the oral and gut microbiomes.

7 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Potential treatment approach to new COVID-19 variant

Researchers in the United States have demonstrated a potential new approach to treating infection with the new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

7 Jan 2021

Researchers provide comprehensive molecular characterization of head and neck cancers

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

7 Jan 2021

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Researchers at Yale University School of Medicine found that SARS-CoV-2 viral loads in saliva are higher for patients with associated risk factors and underlying conditions that lead to severe COVID-19 and death. Thus, saliva viral loads could be used to predict disease severity.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Antibody News and Research

Further Reading

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Researchers receive NIH grant to develop more effective flu vaccines

Study shows P681H mutation is becoming globally prevalent among SARS-CoV-2 sequences

Single-dose nanoparticle vaccine for SARS-CoV-2

New approach to tame botulinum toxin for drug delivery

Single-dose nanoparticle COVID-19 vaccine elicits virus-neutralizing antibody response in mice

Study reveals six-month consequences of COVID-19 in patients discharged from hospital

Scientists gain new insight into how the immune system can be better used to destroy cancer cells

UCSF researchers discover a new way to control immune system's 'natural killer' cells

Advanced nanomaterial-based biosensing platform rapidly detects COVID-19 antibodies

How do SARS-CoV-2 antibodies change over time in recovered patients?

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

Gut and oral microbiomes predict COVID-19 severity

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

Potential treatment approach to new COVID-19 variant

Researchers provide comprehensive molecular characterization of head and neck cancers

SARS-CoV-2 viral load in saliva may be linked to COVID-19 disease severity

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo